Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: Potential applications to cardiovascular disease and diabetes

Proteomics - Clinical Applications

Volumn 7, Issue 7-8, 2013, Pages 528-540

  Yassine, Hussein ^a   Borges, Chad R ^b   Schaab, Matthew R ^b   Billheimer, Dean ^c   Stump, Craig ^d,e   Reaven, Peter ^f   Lau, Serrine S ^c   Nelson, Randall ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^f CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein A I; Cardiovascular disease (CVD); Diabetes; High density lipoprotein (HDL)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COMPLEMENT COMPONENT C3; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ACUTE PHASE RESPONSE; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; COMPLEMENT SYSTEM; CONGESTIVE HEART FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID OXIDATION; HUMAN; IMMUNOASSAY; LIPID METABOLISM; MASS SPECTROMETRIC IMMUNOASSAY; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEOMICS; REVIEW;

APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASE (CVD); DIABETES; HIGH DENSITY LIPOPROTEIN (HDL);

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA;

EID: 84881486980     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200028     Document Type: Review

References (82)

1. Coccheri, S., Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007, 67, 997-1026.
2. Tuomilehto, J., Lindstrom, J., Qiao, Q., Strategies for the prevention of type 2 diabetes and cardiovascular disease. Eur. Heart J. Suppl. 2005, 7, D18-D22.
3. Brunner, E. J., Shipley, M. J., Witte, D. R., Fuller, J. H. et al., Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006, 29, 26-31.
4. Nissen, S. E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457-2471.
5. Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr. et al., Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358, 2545-2559.
6. Duckworth, W., Abraira, C., Moritz, T., Reda, D. et al., Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009, 360, 129-139.
7. Group, A. S., Ginsberg, H. N., Elam, M. B., Lovato, L. C. et al., Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362, 1563-1574.
8. Group, A. S., Cushman, W. C., Evans, G. W., Byington, R. P. et al., Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362, 1575-1585.
9. FDA Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2008.
10. Navab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J. et al., The double jeopardy of HDL. Ann. Med. 2005, 37, 173-178.
11. Kontush, A., Chapman, M. J., Why is HDL functionally deficient in type 2 diabetes? Curr. Diab. Rep. 2008, 8, 51-59.
12. Rothblat, G. H., Phillips, M. C., High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 2010, 21, 229-238.
13. Gowri, M. S., Van der Westhuyzen, D. R., Bridges, S. R., Anderson, J. W., Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2226-2233.
14. Barter, P. J., Nicholls, S., Rye, K. A., Anantharamaiah, G. M. et al., Antiinflammatory properties of HDL. Circ. Res. 2004, 95, 764-772.
15. Panzenbock, U., Stocker, R., Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim. Biophys. Acta. 2005, 1703, 171-181.
16. Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J. et al., Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118, 1259-1267.
17. Navab, M., Hama, S. Y., Hough, G. P., Subbanagounder, G. et al., A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid. Res. 2001, 42, 1308-1317.
18. Chiba, T., Chang, M. Y., Wang, S., Wight, T. N. et al., Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1326-1332.
19. Gordon, S. M., Deng, J. Y., Lu, L. J., Davidson, W. S., Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 2010, 9, 5239-5249.
20. Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S. et al., HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57, 392-410.
21. Niederkofler, E. E., Tubbs, K. A., Kiernan, U. A., Nedelkov, D. et al., Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J. Lipid. Res. 2003, 44, 630-639.
22. Brouillette, C. G., Anantharamaiah, G. M., Engler, J. A., Borhani, D. W., Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim. Biophys. Acta. 2001, 1531, 4-46.
23. Shao, B., Oda, M. N., Bergt, C., Fu, X. et al., Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 2006, 281, 9001-9004.
24. Zheng, L., Nukuna, B., Brennan, M. L., Sun, M. et al., Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 2004, 114, 529-541.
25. Shao, B., Cavigiolio, G., Brot, N., Oda, M. N. et al., Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc. Natl. Acad. Sci. U S A. 2008, 105, 12224-12229.
26. Rader, D. J., Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script. Circulation 2009, 120, 549-552.
27. Nobecourt, E., Davies, M. J., Brown, B. E., Curtiss, L. K. et al., The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 2007, 50, 643-653.
28. Nobecourt, E., Tabet, F., Lambert, G., Puranik, R. et al., Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler. Throm. Vasc. Biol. 2010, 30, 766-U279.
29. Park, K. H., Jang, W., Kim, K. Y., Kim, J. R. et al., Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem. Biophys. Res. Commun. 2010, 392, 295-300.
30. Garner, B., Waldeck, A. R., Witting, P. K., Rye, K. A., Stocker, R., Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 1998, 273, 6088-6095.
31. Garner, B., Witting, P. K., Waldeck, A. R., Christison, J. K. et al., Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J. Biol. Chem. 1998, 273, 6080-6087.
32. Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P. et al., Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290, 2292-2300.
33. Nelson, R. W., Krone, J. R., Bieber, A. L., Williams, P., Mass spectrometric immunoassay. Anal. Chem. 1995, 67, 1153-1158.
34. Nedelkov, D., Population proteomics: investigation of protein diversity in human populations. Proteomics 2008, 8, 779-786.
35. Nedelkov, D., Kiernan, U. A., Niederkofler, E. E., Tubbs, K. A. et al., Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. U S A. 2005, 102, 10852-10857.
36. Nedelkov, D., Tubbs, K. A., Niederkofler, E. E., Kiernan, U. A. et al., High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. Anal. Chem. 2004, 76, 1733-1737.
37. Nelson, R. W., Borges, C. R., Mass spectrometric immunoassay revisited. J. Am. Soc. Mass Spect. 2011, 22, 960-968.
38. Nelson, R. W., Nedelkov, D., Tubbs, K. A., Kiernan, U. A., Quantitative mass spectrometric immunoassay of insulin like growth factor 1. J. Proteome Res. 2004, 3, 851-855.
39. Nelson, R. W., Williams, P., Krone, J. R., in: USPTO (Ed.), USA 2005.
40. Nelson, R. W., Williams, P., Krone, J. R., in: USPTO (Ed.), USA 2007.
41. Niederkofler, E. E., Kiernan, U. A., O'Rear, J., Menon, S. et al., Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ.: Heart Failure 2008, 1, 258-264.
42. Niederkofler, E. E., Tubbs, K. A., Gruber, K., Nedelkov, D. et al., Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal. Chem. 2001, 73, 3294-3299.
43. Tubbs, K. A., Kiernan, U. A., Niederkofler, E. E., Nedelkov, D. et al., Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Anal. Chem. 2006, 78, 3271-3276.
44. Kiernan, U. A., Addobbati, R., Nedelkov, D., Nelson, R. W., Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J. Proteome Res. 2006, 5, 1682-1687.
45. Kiernan, U. A., Nedelkov, D., Nelson, R. W., Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J. Proteome Res. 2006, 5, 2928-2934.
46. Kiernan, U. A., Nedelkov, D., Niederkofler, E. E., Tubbs, K. A. et al., High-throughput affinity mass spectrometry. Methods Mol. Biol. 2006, 328, 141-150.
47. Kiernan, U. A., Nedelkov, D., Tubbs, K. A., Niederkofler, E. E. et al., Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics 2004, 4, 1825-1829.
48. Kiernan, U. A., Nedelkov, D., Tubbs, K. A., Niederkofler, E. E. et al., Selected expression profiling of full-length proteins and their variants in human plasma. Clin. Proteomics J. 2004, 1, 7-16.
49. Kiernan, U. A., Phillips, D. A., Trenchevska, O., Nedelkov, D., Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS One 2011, 6, e17282.
50. Kiernan, U. A., Tubbs, K. A., Gruber, K., Nedelkov, D. et al., High-throughput protein characterization using mass spectrometric immunoassay. Anal. Biochem. 2002, 301, 49-56.
51. Kiernan, U. A., Tubbs, K. A., Nedelkov, D., Niederkofler, E. E. et al., Comparative urine protein phenotyping using mass spectrometric immunoassay. J. Proteome Res. 2003, 2, 191-197.
52. Kiernan, U. A., Tubbs, K. A., Nedelkov, D., Niederkofler, E. E. et al., Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem. Biophys. Res. Commun. 2002, 297, 401-405.
53. Kiernan, U. A., Tubbs, K. A., Nedelkov, D., Niederkofler, E. E. et al., Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett. 2003, 537, 166-170.
54. Borges, C. R., Jarvis, J. W., Oran, P. E., Nelson, R. W., Population studies of vitamin d binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent o-glycosylation patterns. J. Proteome Res. 2008, 7, 4143-4153.
55. Borges, C. R., Jarvis, J. W., Oran, P. E., Rogers, S. P. et al., Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS. J. Biomol. Tech. 2008, 19, 167-176.
56. Borges, C. R., Oran, P. E., Buddi, S., Jarvis, J. W. et al., Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Clin. Chem. 2011, 57, 719-728.
57. Borges, C. R., Rehder, D. S., Jarvis, J. W., Schaab, M. R. et al., Full-length characterization of proteins in human populations. Clin. Chem. 2010, 56, 202-211.
58. Oran, P. E., Jarvis, J. W., Borges, C. R., Nelson, R. W., C-peptide microheterogeneity in type 2 diabetes populations. Proteomics. Clin. Appl. 2010, 4, 1-6.
59. Oran, P. E., Jarvis, J. W., Borges, C. R., Sherma, N. D. et al., Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics. Clin. Appl. 2011, 5, 454-459.
60. Oran, P. E., Sherma, N. D., Borges, C. R., Jarvis, J. W. et al., Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin. Chem. 2010, 56, 1432-1441.
61. Trenchevska, O., Kamcheva, E., Nedelkov, D., Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J. Proteome Res. 2010, 9, 5969-5973.
62. Trenchevska, O., Kamcheva, E., Nedelkov, D., Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 2011, 11, 3633-3641.
63. Trenchevska, O., Nedelkov, D., Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 2011, 9, 19.
64. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B. et al., Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 2004, 3, 235-244.
65. Warren, E. N., Elms, P. J., Parker, C. E., Borchers, C. H., Development of a protein chip: a MS-based method for quantitation of protein expression and modification levels using an immunoaffinity approach. Anal. Chem. 2004, 76, 4082-4092.
66. Krastins, B., Prakash, A., Sarracino, D. A., Nedelkov, D. et al., Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 2013, 46, 399-410.
67. Lopez, M. F., Rezai, T., Sarracino, D. A., Prakash, A. et al., Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56, 281-290.
68. Rehder, D. S., Borges, C. R., Possibilities and pitfalls in quantifying the extent of cysteine sulfenic acid modification of specific proteins within complex biofluids. BMC Biochem. 2010, 11, 25.
69. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics: MCP 2006, 5, 573-588.
70. Reid, J. D., Holmes, D. T., Mason, D. R., Shah, B. et al., Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J. Am. Soc. Mass Spectromet. 2010, 21, 1680-1686.
71. Mason, D. R., Reid, J. D., Camenzind, A. G., Holmes, D. T. et al., Duplexed iMALDI for the detection of angiotensin I and angiotensin II. Methods 2012, 56, 213-222.
72. Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A. et al., Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117, 746-756.
73. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics: MCP 2009, 8, 1860-1877.
74. Yocum, A. K., Chinnaiyan, A. M., Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct. Genomic Proteomic 2009, 8, 145-157.
75. Abbatiello, S., Schilling, B., Mani, D., Feng, X. et al., Development and application of a system suitability standard and protocol to assess data quality in LC-MRM-MS across multiple MS platforms http://proteomics.cancer.gov/programs/CPTAC 2010.
76. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., MRM-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics: MCP 2009, 8, 1860-1877.
77. Davidsson, P., Hulthe, J., Fagerberg, B., Camejo, G., Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 156-163.
78. Davidson, W. S., Silva, R. A., Chantepie, S., Lagor, W. R. et al., Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 870-876.
79. McPherson, P. A., Young, I. S., McKibben, B., McEneny, J., High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J. Lipid Res. 2007, 48, 86-95.
80. Parker, C. E., Pearson, T. W., Anderson, N. L., Borchers, C. H., Mass-spectrometry-based clinical proteomics-a review and prospective. Analyst 2010, 135, 1830-1838.
81. Sacks, S. S., Are routine testosterone assays good enough? Clin. Biochem. Rev. 2005, 26, 43-45.
82. Fullerton, S. M., Buchanan, A. V., Sonpar, V. A., Taylor, S. L. et al., The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster. Hum. Genet. 2004, 115, 36-56.